Sei Investments Co. Lowers Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

Sei Investments Co. reduced its position in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 3.7% during the 4th quarter, HoldingsChannel reports. The firm owned 263,582 shares of the biotechnology company’s stock after selling 10,165 shares during the period. Sei Investments Co.’s holdings in Ascendis Pharma A/S were worth $36,287,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of ASND. American Century Companies Inc. grew its position in shares of Ascendis Pharma A/S by 17.5% during the 4th quarter. American Century Companies Inc. now owns 407,294 shares of the biotechnology company’s stock worth $56,072,000 after buying an additional 60,548 shares in the last quarter. Corient Private Wealth LLC bought a new position in Ascendis Pharma A/S during the 4th quarter worth about $450,000. HighTower Advisors LLC bought a new position in Ascendis Pharma A/S during the 4th quarter worth about $484,000. Aigen Investment Management LP increased its position in Ascendis Pharma A/S by 40.0% during the 4th quarter. Aigen Investment Management LP now owns 2,332 shares of the biotechnology company’s stock valued at $321,000 after purchasing an additional 666 shares during the period. Finally, Proficio Capital Partners LLC bought a new stake in shares of Ascendis Pharma A/S in the 4th quarter valued at about $1,725,000.

Wall Street Analyst Weigh In

ASND has been the topic of several research reports. Evercore ISI lifted their price objective on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the company an “outperform” rating in a report on Tuesday, February 18th. UBS Group started coverage on Ascendis Pharma A/S in a report on Tuesday, January 7th. They issued a “buy” rating and a $196.00 price target on the stock. Morgan Stanley set a $180.00 price objective on Ascendis Pharma A/S in a research note on Tuesday, February 18th. JPMorgan Chase & Co. raised their target price on shares of Ascendis Pharma A/S from $168.00 to $200.00 and gave the company an “overweight” rating in a research note on Tuesday, March 18th. Finally, Cantor Fitzgerald raised their price target on Ascendis Pharma A/S from $170.00 to $200.00 and gave the stock an “overweight” rating in a report on Tuesday, February 25th. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat, Ascendis Pharma A/S currently has a consensus rating of “Moderate Buy” and a consensus target price of $204.64.

Ascendis Pharma A/S Stock Up 1.2 %

Shares of ASND stock opened at $167.99 on Tuesday. Ascendis Pharma A/S has a 52-week low of $111.09 and a 52-week high of $169.37. The stock has a market cap of $10.20 billion, a PE ratio of -23.66 and a beta of 0.62. The business has a 50-day simple moving average of $142.05 and a 200-day simple moving average of $136.15.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.32) by $0.64. Sell-side analysts anticipate that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.